Ultime notizie per Janux Therapeutics (NASDAQ:JANX) Azioni

Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Janux Therapeutics Inc

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

News

Guidance

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent. This is a 10.60 percent decrease over sales of $92.48 million the same period last year.

Earnings

Earnings Misses

ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

Earnings Beats

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.

INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent. The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent. This is a 135.57 percent increase over sales of $22.169 million the same period last year.

INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 39.33 percent increase over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $28.07 million which beat the analyst consensus estimate of $28.02 million by 0.20 percent. This is a 26.41 percent increase over sales of $22.21 million the same period last year.

OUST

Ouster Q3 EPS $(0.54) Beats $(0.57) Estimate, Sales $28.07M Beat $28.02M Estimate

AFRM

Affirm Sees FY25 GMV OF More Than $34B

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

AXDX

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

Financial Outlook for Full Year 2024
The following tables summarize Getty Images' updated fiscal year 2024 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Updated 2024 Guidance</td>
<td>Prior 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$934 million to $943 million</td>
<td>$924 million to $943 million</td>
</tr>
<tr>
<td>Revenue YoY</td>
<td>1.9% to 2.9%</td>
<td>0.9% to 2.9%</td>
</tr>
<tr>
<td>Revenue YoY, Currency Neutral</td>
<td>1.6% to 2.6%</td>
<td>1.0% to 3.0%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$292 million to $294 million</td>
<td>$290 million to $294 million</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY</td>
<td>(3.1)% to (2.5)%</td>
<td>(3.8)% to (2.5)%</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY, Currency Neutral</td>
<td>(3.4)% to (2.8)%</td>
<td>(3.6)% to (2.3)%</td>
</tr>
</tbody>
</table>
</figure>
 Guidance has been updated to reflect the Company's financial performance year to date and the impact of foreign currency exchange rates on both Revenue and Adjusted EBITDA.

GETY

Getty Images Raises FY24 Revenue From $924M-$943M To $934M-$943M Vs $932.61M Est.

Affirm Sees Q2 Revenue $770M-$810M

Corpay Narrows FY24 Total Revenue Outlook From $3.975B - $4.025B To $3.98B - $4.01B (Est $3.989B), Adjusted EPS Forecast From $18.85 - $19.15. To $18.90 - $19.10 (Est $18.96)

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) narrows FY2024 sales outlook from $269.60 million-281.60 million to $272.60 million-278.60 million.

UPLD

Upland Software Narrows FY2024 Sales Guidance from $269.60M-281.60M to $272.60M-278.60M  VS Est.274.57M

Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $1.01 by 6.93 percent. The company reported quarterly sales of $112.716 million which beat the analyst consensus estimate of $110.552 million by 1.96 percent. This is a 414.00 percent increase over sales of $21.929 million the same period last year.

VINP

Vinci Partners Inv Q3 2024 Adj. EPS $1.08 Beats $1.01 Estimate, Sales $112.716M Beat $110.552M Estimate

Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. The company reported quarterly sales of $406.019 million which beat the analyst consensus estimate of $392.579 million by 3.42 percent. This is a 16.48 percent increase over sales of $348.571 million the same period last year.

GDOT

Green Dot Q3 2024 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $406.019M Beat $392.579M Estimate

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.19) by 68.42 percent. This is a 135.29 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $46.77 million which beat the analyst consensus estimate of $41.95 million by 11.49 percent. This is a 5.86 percent decrease over sales of $49.69 million the same period last year.

CLFD

Clearfield Q4 EPS $(0.06) Beats $(0.19) Estimate, Sales $46.77M Beat $41.95M Estimate

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report), Lyell Immuno...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)

Janux Therapeutics: Buoyed By Buyout Speculation

Janux initiated at Stifel with Buy on upcoming data update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his Buy ...

Promising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data Release

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating on October 31. Marc Frahm's rating is based on p...

Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in mCRPC Treatment

Janux Therapeutics GAAP EPS of -$0.51 misses by $0.13, revenue of $0.44M misses by $1.23M

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target ...

Janux Therapeutics Inc (JANX) Receives a Buy from BTIG

Scotiabank analyst George Farmer maintained a Hold rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $42.00...

Comments

Janux Therapeutics

Notizie

Ultime notizie per Janux Therapeutics (NASDAQ:JANX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO